Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026
Globe Newswire•19/10/2026•07:00 ET
0
Key Highlights
- ➤Parabilis Medicines (PBLS) will present updated zolucatetide data at ESMO Congress 2026
- ➤June 22, 2026 data cutoff covers dose escalation and dose optimization trial portions
- ➤Dose optimization is designed to select dose and schedule for planned Phase 3 trial
- ➤Zolucatetide has FDA Fast Track and Orphan Drug Designations for desmoid tumors
Oral presentation will include updated data from the ongoing Phase 1/2 trial, with dose optimization arm designed to inform dose and regimen selection for Phase 3 registrational trial in desmoid tumors
Company to host webcast on Saturday, October 24, 2026, at 6 p.m. CEST / 12 p.m. EDT
Get started
Create a free account to read the full story.